Do you have any idea the actual size of TEVA's R&D budget is? They make 2 dozen similar investments a year. The investment in Rexahn doesn't even register as a whole 1% of their annual R&D budget. It's along the lines of .000001% in a given year.
But to answer your question, will there be a buyout? The answer is no. Rexahn has generated exactly ZERO clinical data supporting any of their candidates or claims for that matter.
Seradaxin was an abject failure and we knew it would be since phase I data was out.
I have not witnessed a more poorly run company in a long time.